Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Atalay, G.
Right arrow Articles by Piccart, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atalay, G.
Right arrow Articles by Piccart, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1346-1363, 2003
© 2003 European Society for Medical Oncology

Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer

G. Atalay, F. Cardoso, A. Awada and M. J. Piccart+

Jules Bordet Institute, Department of Medical Oncology, Brussels, Belgium

Received 11 November 2002; revised 27 February 2003; accepted 22 April 2003

Abstract

From the early experience with tamoxifen to the current use of Herceptin®, targeted therapy has been proven to be an important part of breast cancer (BC) treatment. In the last decade, advances in molecular biology have allowed scientists to design highly individualized, ‘smart’ pharmaceuticals, capable of manipulating the growth factor pathways and the genes that are involved in the development and maintenance of the malignant phenotype. The epidermal growth factor receptor (EGFR) family, as one of the best studied growth factor pathways in cancer, resembles a ‘treasure island’ by providing a wide range of biologically relevant targets involved in breast carcinogenesis. While a large number of new agents targeting this pathway are continuingly being tested in preclinical experiments, clinicians are witnessing the migration of some of these agents to daily practice. The aim of this review is to provide clinicians with an updated synopsis of the most advanced anti-erbB therapeutic strategies with activity against BC.

Key words: Akt, breast cancer, EGFR (ErbB) family, HER-2, MAPK


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
B. Moy and P. E. Goss
Lapatinib-Associated Toxicity and Practical Management Recommendations
Oncologist, July 1, 2007; 12(7): 756 - 765.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. Rolland, Z. Madjd, L. Durrant, I. O Ellis, R. Layfield, and I. Spendlove
The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease
Endocr. Relat. Cancer, March 1, 2007; 14(1): 73 - 80.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Moy and P. E. Goss
Lapatinib: Current Status and Future Directions in Breast Cancer
Oncologist, November 1, 2006; 11(10): 1047 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
T. Yaoi, S. Chamnongpol, X. Jiang, and X. Li
Src Homology 2 Domain-based High Throughput Assays for Profiling Downstream Molecules in Receptor Tyrosine Kinase Pathways
Mol. Cell. Proteomics, May 1, 2006; 5(5): 959 - 968.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. A. Menendez, L. Vellon, and R. Lupu
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
Ann. Onc., August 1, 2005; 16(8): 1253 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R Duncan, M J Vicent, F Greco, and R I Nicholson
Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S189 - S199.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Bernard-Marty, F. Cardoso, and M. J. Piccart
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Oncologist, November 1, 2004; 9(6): 617 - 632.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. U. Lin, J. R. Bellon, and E. P. Winer
CNS Metastases in Breast Cancer
J. Clin. Oncol., September 1, 2004; 22(17): 3608 - 3617.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.